MICAD adds 17 molecular imaging, contrast agents
The Molecular Imaging Probes and Contrast Agents Database (MICAD), created at the National Center for Biotechnology Information, National Institutes of Health via the PubMed/MedLine databases and other sources, has added 17 new agents, increasing the total to 841 agents in the database.

The new PET agents are:
  • 64Cu-PEI  which targets heparin sulfate proteoglycans;
  • [11C]Methoxy-Sch225336 which targets cannabinoid CB2 receptor (CB2R);
  • [11C]SU11274 which targets mesenchymal-epithelial transition factor (MET); and
  • [11C]SL25.1188 which targets monoamine oxidase B (MAO-B).

The new SPECT agents are:
  • 67Ga-DOTA-GlyGlu-CycMSH which targets melanocortin-1 receptor (MC1R);
  • [186Re]MAMA-HBP and [186Re]MAMA-BP which both targets farnesyl disphosphate (pyrophosphate) synthase;
  • [125I]IodoDPA-713 which targets peripheral-type benzodiazepine receptor (PBR), also known as translocator protein (TSPO);
  • [125I]-BH-Exendin(9-39) which targets glucagon-like peptide-1 (GLP-1) receptor;
  • 125I-EGFR-Fab which targets epidermal growth factor receptor (EGFR);
  • 111In-[DTPA1-Lys3,Tyr4]-BN which targets gastrin-releasing peptide receptor (GRPR);
  • 111In-DOTA-E3-uroguanylin which targets receptor guanylate cyclase C (GC-C);
  • 99mTc-PR81 which targets mucin; and
  • 99mTc-DTPA-TOR which targets estrogen receptor.

The new optical agents are:
  • tAB50-Cy5 which targets caspase-3 and caspase-7;
  • Legumain probe 1 which targets legumain/asparaginyl endopeptidase; and
  • AnxB12 Cys101,Cys260-IANBD which targets phosphatidylserine.